Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
4106880
Reference Type
Journal Article
Title
Effect of captopril, losartan, and bradykinin on early steps of insulin action (Retracted article. See vol. 65, pg. 1128, 2016)
Author(s)
Carvalho, CRO; Thirone, ACP; Gontijo, JAR; Velloso, LA; Saad, MJA
Year
1997
Is Peer Reviewed?
Yes
Journal
Diabetes
ISSN:
0012-1797
EISSN:
1939-327X
Volume
46
Issue
12
Page Numbers
1950-1957
Language
English
PMID
9392479
DOI
10.2337/diabetes.46.12.1950
Web of Science Id
WOS:A1997YH80500005
URL
https://diabetesjournals.org/diabetes/article/46/12/1950/10110/Effect-of-Captopril-Losartan-and-Bradykinin-on
Exit
Relationship(s)
has retraction
4099723
Statement of Retraction. Effect of Captopril, Losartan, and Bradykinin on Early Steps of Insulin Action. Diabetes 1997;46:1950-1957. DOI: 10.2337/diab.46.12.1950
has retraction
11896993
Expression of concern
Abstract
Insulin initiates its metabolic and growth-promoting effects by binding to the a subunit of its receptor, thereby activating the kinase in the beta subunit. This event leads to tyrosyl phosphorylation of its cytosolic substrate, insulin receptor substrate 1 (IRS-1), which in turn associates with and activates phosphatidylinositol (PI) 3-kinase. The clinical use of ACE inhibitors has been associated with increased insulin sensitivity. However, the exact molecular mechanism is unknown. In the present study, we examined the phosphorylation status of the insulin receptor and IBS-I, as well as the association between IRS-1 and PI 3-kinase in the liver and muscle of 20-month-old rats treated acutely with captopril, using immunoprecipitation with antipeptide antibodies to the insulin receptor and IRS-1, and immunoblotting with antiphosphotyrosine and anti-PI 3-kinase antibodies. Insulin stimulation increased receptor autophosphorylation to 462 +/- 253% (P < 0.05) in the liver and 697 +/- 78% (P < 0.001) in the muscle of ACE inhibitor-treated rats. There were also increases to 250 +/- 17% (P < 0.001) and 280 +/- 50% (P < 0.05) in the insulin-stimulated IRS-1 phosphorylation levels in the liver and muscle, respectively, of animals treated with captopril. The insulin-stimulated IRS-1 association with PI 3-kinase rose to 305 +/- 20% (P < 0.001) in Liver and 267 +/- 48% (P < 0.05) in muscle. Losartan, an ANG receptor blocker, had no significant effect on insulin-stimulated IRS-1 phosphorylation in both tissues. The acute administration of bradykinin increased insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS-1 in the liver and muscle. These data demonstrate that ACE inhibitors modulate the early steps of insulin signaling, and that this effect may be simulated by the administration of bradykinin.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity